<DOC>
	<DOCNO>NCT01447784</DOCNO>
	<brief_summary>House Dust Mites ( HDM ) arachnids infest bedding , carpet , upholstered furniture fabric . Like many allergen , exposure HDM allergen sensitise patient associate poor lung function , great medication requirement asthma symptom well chronic rhinosinusitis symptom . In contrast allergen , evidence HDMA lead development asthma , addition exacerbate pre-existing asthma HDM-sensitised patient . ToleroMune HDM novel , synthetic , allergen-derived peptide desensitise vaccine , currently develop treatment HDM allergy This study look efficacy , safety tolerability three dos ToleroMune HDM HDM allergic subject follow challenge HDM allergen Environmental Exposure Chamber ( EEC ) ) .</brief_summary>
	<brief_title>ToleroMune House Dust Mites ( HDM ) Exposure Chamber Study</brief_title>
	<detailed_description>This study design randomise , double-blind , placebo-controlled , parallel group study evaluate safety tolerability ToleroMune HDM HDM allergic subject allergic rhinoconjunctivitis . The efficacy ToleroMune Ragweed explore subject use EEC . The study consist 3 study period . In Period 1 , Screening perform maximum 16 week randomisation may consist one two visit clinic , Investigator 's discretion . Baseline Challenge consist 3 visit EEC . Eligible subject complete daily diary card home two week follow final visit EEC . In Period 2 , subject cohort comply inclusion/exclusion criterion randomise one four group receive treatment 11 visit 3 dose period subject . Within dose period visit take place interval 4 week ( 28Â±2 day ) . There also two EEC visit treatment period one post treatment EEC visit . Following final visit EEC , subject complete daily diary card home two week . In Period 3 , Follow-up conduct 16-21 day final EEC visit .</detailed_description>
	<criteria>Inclusion criterion Male female , age 1865 year . Minimum 1year documented history rhinoconjunctivitis exposure HDM . Positive skin prick test Der p allergen . Minimum qualify rhinoconjunctivitis symptom score Exclusion criterion History asthma ( asthma childhood . A history anaphylaxis HDM allergen . Subjects FEV1 &lt; 80 % predict . Subjects tolerate baseline challenge EEC . Subjects administration epinephrine contraindicate ( e.g . subject acute chronic symptomatic coronary heart disease severe hypertension ) . A history severe drug allergy , severe angioedema anaphylactic reaction food . A history significant disease disorder ( e.g . cardiovascular , pulmonary , gastrointestinal , liver , renal , neurological , musculoskeletal , endocrine , metabolic , neoplastic/malignant , psychiatric , major physical impairment ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>HDM allergy</keyword>
	<keyword>Rhinoconunctivitis</keyword>
	<keyword>Environmental Exposure Chamber</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>ToleroMune HDM</keyword>
</DOC>